

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Tushar A. Kshirsagar *et al.*
Serial No.: 10/596,895
Confirmation No.: 1940
Filed: January 16, 2007
For: PIPERAZINE, [1,4]DIAZEPANE, [1,4]DIAZOCANE, AND
[1,5]DIAZOCANE FUSED IMIDAZO RING
COMPOUNDS
Examiner: Noble E. Jarrell
Art Unit: 1624

Certificate of Electronic Filing Under 37 CFR § 1.8

I hereby certify that this paper (along with any paper referred to as being attached or enclosed) is being transmitted via the Office electronic filing system in accordance with § 1.6(a)(4).

Dated: April 26, 2010

/Sara J. L. Douglas/
Sara J. L. Douglas

STATEMENT FILED PURSUANT TO THE DUTY OF
DISCLOSURE UNDER 37 CFR §§ 1.56, 1.97 AND 1.98

Sir:

Pursuant to the duty of disclosure under 37 C.F.R. §§ 1.56, 1.97 and 1.98, the Applicant requests consideration of this Information Disclosure Statement.

PART I: Compliance with 37 C.F.R. § 1.97

This Information Disclosure Statement is being filed with a Request for Continued Examination under 37 C.F.R. § 1.114. Therefore, no fee or certification is required.

PART II: Information Cited

The Applicant hereby makes of record in the above-identified application the information listed on the attached form PTO-1449 (modified PTO/SB/08). The order of presentation of the references should not be construed as an indication of the importance of the references.

The above-identified U.S. application claims priority to application International PCT Application, PCT/US04/43474. If the Examiner has not had the benefit of review of the file history of International PCT Application, PCT/US04/43474, then he/she is asked to contact the undersigned, who will provide a copy of same.

The Applicant would also like to bring to the Examiner's attention the enclosed search reports from corresponding or related international or foreign patent applications:

Serial No.	Date of Mailing	Type(s) of Communication	Docket No.
PCT/US2004/043474	June 20, 2005	International Search Report and Written Opinion	C1271.70050WO00
PCT/US2004/043474	April 3, 2006	International Preliminary Report on Patentability	C1271.70050WO00

PART III: Remarks

Documents cited anywhere in the Information Disclosure Statement are enclosed unless otherwise indicated. It is respectfully requested that:

1. The Examiner consider completely the cited information, along with any other information, in reaching a determination concerning the patentability of the present claims;
2. The enclosed form PTO-1449 (modified PTO/SB/08) be signed by the Examiner to evidence that the cited information has been fully considered by the Patent and Trademark Office during the examination of this application;
3. The citations for the information be printed on any patent which issues from this application.

By submitting this Information Disclosure Statement, the Applicant makes no representation that a search has been performed, of the extent of any search performed, or that more relevant information does not exist.

By submitting this Information Disclosure Statement, the Applicant makes no representation that the information cited in the Statement is, or is considered to be, material to patentability as defined in 37 C.F.R. § 1.56(b).

By submitting this Information Disclosure Statement, the Applicant makes no representation that the information cited in the Statement is, or is considered to be, in fact, prior art as defined by 35 U.S.C. § 102.

Notwithstanding any statements by the Applicant, the Examiner is urged to form his or her own conclusion regarding the relevance of the cited information.

An early and favorable action is hereby requested.

Respectfully submitted,

By: /C. Hunter Baker/
C. Hunter Baker, M.D., Ph.D.
Registration Number 46,533
Wolf, Greenfield & Sacks, P.C.
600 Atlantic Avenue
Boston, Massachusetts 02210-2206
Telephone: (617) 646-8000

Docket No.: C1271.70050US01
Date: April 26, 2010
xNDDx